Mid-Morning Market Update: Markets Open Higher; Goldman Sachs Tops Q3 Expectations

Following the market opening Wednesday, the Dow traded up 0.25% to 28751.55 while the NASDAQ rose 0.28% to 11,897.16. The S&P also rose, gaining 0.25% to 3,520.75.


The U.S. has the highest number of coronavirus cases and deaths in the world, reporting a total of 7,859,360 cases with around 215,910 deaths. India confirmed a total of at least 7,239,380 confirmed cases and 110,580 deaths, while Brazil reported over 5,113,620 COVID-19 cases with 150,990 deaths. In total, there were at least 38,195,650 cases of COVID-19 worldwide with over 1,087,340 deaths, according to data compiled by Johns Hopkins University.

Leading and Lagging Sectors


Energy shares rose 1.4% on Wednesday. Meanwhile, top gainers in the sector included Concho Resources Inc. CXO, up 11%, and Centennial Resource Development, Inc. CDEV, up 11%.

In trading on Wednesday, financial shares fell 0.1%.


Top Headline


Goldman Sachs Group Inc GS reported better-than-expected results for its third quarter.

Goldman Sachs reported quarterly earnings of $9.68 per share, beating analysts’ estimates of $5.57 per share. The company posted sales of $10.78 billion, surpassing expectations of $9.46 billion.


Equities Trading UP


Interpace Biosciences, Inc. IDXG shares shot up 45% to $4.31. Interpace Biosciences said the Audit Committee investigation found billing and compliance complaints unsubstantiated.

Shares of Allscripts Healthcare Solutions, Inc. MDRX got a boost, shooting 34% to $11.11 after the company agreed to sell its CarePort Health business to WellSky for $1.35 billion.

AnaptysBio, Inc. ANAB shares were also up, gaining 27% to $22.54 after Guggenheim upgraded the stock from Neutral to Buy and announced a price target of $36 per share. AnaptysBio yesterday reported positive topline data from GALLOP Phase 2 clinical trial of imsidolimab in moderate-to-severe generalized pustular psoriasis.

 


Equities Trading DOWN

Cyclerion Therapeutics, Inc. CYCN shares tumbled 46% to $3.8525 following a couple of clinical trial updates from the company. Cyclerion said its mid-stage investigational asset olinciguat did not show adequate activity to support further internal clinical development of it as a potential treatment for sickle cell disease. Separately, the company announced positive results from a Phase 1 translational pharmacology study of IW-6463, a soluble guanylate cyclase stimulator being developed for CNS disorders.

Shares of Enzo Biochem, Inc. ENZ were down 17% to $2.16. Enzo Biochem reported fourth-quarter revenues of $19.5 million, down 6.6% year-over-year, while on a GAAP basis, the net loss narrowed from 11 cents per share to 7 cents per share.

AMC Entertainment Holdings, Inc. AMC was down, falling 17% to $2.95. The world’s biggest chain of theaters - AMC Entertainment is mulling options for respite from debt, that includes potential bankruptcy, Bloomberg reported.


Commodities


In commodity news, oil traded down 0.4% to $40.05, while gold traded up 0.4% to $1,902.60.


Silver traded up 0.8% Wednesday to $24.320 while copper rose 0.4% to $3.0560.


Euro zone


European shares were mostly lower today. The eurozone’s STOXX 600 fell 0.1%, the Spanish Ibex Index rose 0.3%, while Italy’s FTSE MIB Index gained 0.3%. Meanwhile, the German DAX 30 declined 0.1%, French CAC 40 slipped 0.2% and London’s FTSE 100 slipped 0.2%.

Consumer prices in Spain fell 0.4% year-over-year in September after declining 0.5% in the previous month.


Economics

The Producer Price Index rose 0.4% for September, versus analysts’ expectations for a 0.2% increase.

Federal Reserve Bank of Dallas President Robert Kaplan will speak at 6:00 p.m. ET.

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Date
ticker
name
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In: EarningsNewsPenny StocksEurozoneCommoditiesGlobalIntraday UpdateMarketsMid-Morning Market Update
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!